Analysts Set Bicara Therapeutics Inc. (NASDAQ:BCAX) Price Target at $31.86

Bicara Therapeutics Inc. (NASDAQ:BCAX) has been given an average recommendation of “Buy” by the nine ratings firms that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $31.86.

A number of research analysts have commented on BCAX shares. Wedbush reiterated an “outperform” rating and set a $30.00 price objective on shares of Bicara Therapeutics in a research note on Friday, May 23rd. Wells Fargo & Company upgraded shares of Bicara Therapeutics from an “underweight” rating to an “equal weight” rating and set a $8.00 price target on the stock in a research report on Friday, May 23rd. Stifel Nicolaus set a $48.00 price target on shares of Bicara Therapeutics in a research report on Thursday, March 27th. Wall Street Zen downgraded shares of Bicara Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, May 22nd. Finally, HC Wainwright reduced their price target on shares of Bicara Therapeutics from $44.00 to $41.00 and set a “buy” rating on the stock in a research report on Friday, May 16th.

Bicara Therapeutics Trading Up 5.5%

NASDAQ BCAX opened at $10.79 on Monday. Bicara Therapeutics has a 12 month low of $7.80 and a 12 month high of $28.09. The company’s fifty day moving average price is $10.88 and its two-hundred day moving average price is $12.38.

Bicara Therapeutics (NASDAQ:BCAX) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($0.68) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.28). Analysts predict that Bicara Therapeutics will post -2.59 EPS for the current year.

Institutional Trading of Bicara Therapeutics

A number of large investors have recently modified their holdings of the company. Red Tree Management LLC acquired a new stake in shares of Bicara Therapeutics in the 4th quarter worth about $55,230,000. Vestal Point Capital LP increased its stake in Bicara Therapeutics by 290.0% during the 1st quarter. Vestal Point Capital LP now owns 2,768,975 shares of the company’s stock valued at $36,080,000 after buying an additional 2,058,975 shares during the period. Adage Capital Partners GP L.L.C. increased its stake in Bicara Therapeutics by 171.9% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 2,175,265 shares of the company’s stock valued at $37,893,000 after buying an additional 1,375,265 shares during the period. Braidwell LP increased its stake in Bicara Therapeutics by 8.1% during the 1st quarter. Braidwell LP now owns 2,162,803 shares of the company’s stock valued at $28,181,000 after buying an additional 162,144 shares during the period. Finally, Deep Track Capital LP increased its stake in Bicara Therapeutics by 151.0% during the 4th quarter. Deep Track Capital LP now owns 2,000,000 shares of the company’s stock valued at $34,840,000 after buying an additional 1,203,148 shares during the period.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.